CVS Q3 Earnings: Separation Plan and Raised Guidance
💡 Key Takeaway
CVS Health's strong Q3 results, raised guidance, and strategic separation plan signal a bullish outlook for the stock.
CVS Q3 Earnings: What You Need to Know
CVS Health reported third-quarter earnings that beat expectations, with adjusted EPS of $2.15 versus the consensus of $2.05. Revenue came in at $89.8 billion, slightly above estimates. The company also raised its full-year 2023 guidance and provided strong 2026 and 2027 EPS targets of $8.20+ and $8.65+, respectively.
Management highlighted that leverage targets were achieved ahead of schedule, and cash flow guidance was improved. The earnings call focused on the planned separation of the pharmacy and consumer wellness segment, which the company believes will unlock shareholder value.
The separation, expected to be completed in 2024, will create two distinct companies: one focused on pharmacy and consumer wellness, and the other on health insurance and health services. CVS plans to retain a significant ownership stake in the new pharmacy company.
Investors reacted positively to the news, with CVS shares rising in pre-market trading. The strong operational performance across segments, particularly in the health insurance division, drove the upbeat results.
What This Means for Me
Why This Matters for CVS Stock
The planned separation is a strategic move that could unlock significant value for shareholders. By separating the pharmacy business from the insurance and health services segments, CVS can focus on high-growth areas and allow the pharmacy unit to operate with greater flexibility.
The raised guidance for 2026 and 2027 demonstrates management's confidence in the company's long-term growth trajectory. The EPS targets are well above current analyst estimates, suggesting potential upside for the stock.
Achieving leverage targets ahead of schedule and improving cash flow guidance indicate strong financial health. This gives CVS the flexibility to invest in growth initiatives and return capital to shareholders.
The positive sentiment from Polygon Insights, with a sentiment score of positive, reflects the market's approval of the strategic direction. The stock could see further upside as the separation progresses and the company continues to deliver strong results.
Stock to Watch
| Stocks | Impact | Analysis | |
|---|---|---|---|
| CVS | Positive | Strong Q3 beat, raised guidance, and strategic separation plan position CVS for upside. The separation could unlock value and improve focus. |
Source: Zacks Investment Research
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight

Buy CVS for potential upside from strong fundamentals and value-unlocking separation.
CVS beat earnings, raised guidance, and is executing a strategic separation that could create significant shareholder value. The stock trades at a reasonable valuation relative to its growth prospects.
What This Means for Me

Read More
CVS Health to Split: What It Means for Investors
Bullish CVS's planned separation, balance sheet strength, and Medicare Advantage recovery make it a compelling long-term value play.
CVSNov 15, 2026CAH Q1 Earnings: Raised Outlook and Specialty Growth Shine
Bullish Cardinal Health's strong Q1 results, raised guidance, and long-term CVS contract renewal underscore its growth trajectory in specialty pharmaceuticals, making CAH an attractive investment.
CAHCVSNov 6, 2026NRXP Q3: Revenue Miss and Strong Sell Rating Spell Trouble
Bearish NRx Pharmaceuticals missed revenue estimates and carries a Zacks Rank #5 (Strong Sell), suggesting further downside risk for the stock.
NRXPANov 16, 2026

